United Therapeutics Corp $ 91.89 0.01 (0.01%)
On watch
Volume:
152,546
Avg Vol (1m):
394,465
Market Cap $:
4.03 Bil
Enterprise Value $:
3.46 Bil
P/E (TTM):
0.00
P/B:
1.46
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.57 | ||
| Equity-to-Asset | 0.68 | ||
| Debt-to-Equity | 0.37 | ||
| Debt-to-EBITDA | -16.95 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 3.76 | ||
| Beneish M-Score | -2.69 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -7.87 | ||
| Net Margin % | -6.04 | ||
| ROE % | -3.49 | ||
| ROA % | -2.49 | ||
| ROC (Joel Greenblatt) % | -13.26 | ||
| 3-Year Revenue Growth Rate | 8.9 | ||
| 3-Year EBITDA Growth Rate | -4.5 | ||
| 3-Year EPS without NRI Growth Rate | 1.7 |
Valuation Rank | 9/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 8.95 | ||
| PB Ratio | 1.46 | ||
| PS Ratio | 2.66 | ||
| EV-to-EBIT | -33.61 | ||
| EV-to-EBITDA | -58.62 | ||
| EV-to-Revenue | 2.28 | ||
| Shiller PE Ratio | 12.62 | ||
| Current Ratio | 4.11 | ||
| Quick Ratio | 3.91 | ||
| Days Inventory | 295.87 | ||
| Days Sales Outstanding | 44.11 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.58 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 0.7 | ||
| Price-to-Median-PS-Value | 0.68 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.27 | ||
| Earnings Yield (Greenblatt) % | -2.98 | ||
| Forward Rate of Return (Yacktman) % | 30.3 |